HITOX

Product Overview

HITOX (Hitox Inj.) is a South Korean botulinum toxin type A injectable medicine developed and manufactured by BMI Korea Co., Ltd. Available in 50U, 100U and 200U vial strengths, HITOX contains Clostridium botulinum toxin type A with human serum albumin and sodium chloride as excipients. The product is supplied as a vacuum-dried powder in a sterile vial and requires preparation according to its approved prescribing information. HITOX is authorized in South Korea for the temporary improvement of moderate to severe glabellar lines in adults aged 19 to 65.

Key Features

• Three Vial Strengths: HITOX is manufactured in 50-unit, 100-unit and 200-unit formulations. Each strength has a separate Korean pharmaceutical registration and defined packaging specifications.
• Botulinum Toxin Type A: The active ingredient is Clostridium botulinum toxin type A, a neurotoxin that temporarily inhibits acetylcholine release at cholinergic nerve terminals.
• Human Serum Albumin and Sodium Chloride: The registered formulation contains human serum albumin and sodium chloride as excipients. These ingredients are listed in the Korean regulatory documentation for all three strengths.
• Vacuum-Dried Powder Formulation: HITOX is presented as a white to pale-yellow vacuum-dried powder in a clear vial. The product is not supplied as a ready-to-inject liquid formulation.
• Refrigerated Storage: The Korean pharmaceutical registrations specify storage at 2–8°C in a sealed container. Shelf life and package configurations differ between the registered strengths.

Composition & Specifications

The specifications above describe the Korean-registered HITOX product family. Individual strengths have separate registration codes, packaging configurations and labeled shelf lives. Export-only and domestic presentations should not be assumed to have identical regulatory status. Verify the original carton and current prescribing information for the selected product.

How HITOX Works

Botulinum toxin type A acts at cholinergic nerve terminals, where it interferes with the release of acetylcholine, a neurotransmitter involved in neuromuscular signaling. The toxin's light chain cleaves SNAP-25, a protein required for synaptic vesicle fusion and neurotransmitter release.

By temporarily reducing acetylcholine release, botulinum toxin type A decreases activity in the affected muscles. In appropriately authorized aesthetic applications, this mechanism can reduce the appearance of dynamic facial wrinkles associated with repeated muscle contraction.

HITOX is approved in South Korea for the temporary improvement of moderate to severe glabellar lines in adults aged 19–65. The product's other potential therapeutic or aesthetic applications should not be treated as approved indications without specific regulatory authorization.

Botulinum toxin potency units are specific to each manufacturer's product and biological activity assay. HITOX units cannot be directly converted to or considered interchangeable with the units of other botulinum toxin brands.

Available Variants

The HITOX product family includes 50U, 100U and 200U formulations manufactured by BMI Korea. All three contain botulinum toxin type A with human serum albumin and sodium chloride. Their principal differences are labeled potency, packaging configuration and registered shelf life.

Shelf-life figures refer to the Korean regulatory records reviewed for each strength. The actual expiration date printed on the supplied package takes precedence. Not every registered box quantity is necessarily available through every commercial channel. Confirm the exact product strength and package before procurement.

Professional Product Selection Considerations

Professional buyers comparing HITOX formulations should distinguish the registered strengths, packaging quantities, shelf lives and market-specific authorizations. Vial potency is a product specification, not a recommendation for clinical dosing.

• Confirm the Correct Vial Strength: Identify HITOX 50U, 100U or 200U according to the labeled product strength. Different vial strengths should not be confused with recommended treatment doses.
• Verify Packaging Quantity: The Korean registration specifies a single-vial box for HITOX 50U, while 100U and 200U also have registered 10-vial box configurations. Verify the supplied commercial SKU.
• Review Excipients: All three registered strengths list human serum albumin and sodium chloride. The current prescribing information should be reviewed for hypersensitivity warnings and contraindications.
• Maintain Refrigerated Conditions: HITOX requires storage at 2–8°C. Professional procurement should account for the refrigerated distribution and storage requirements.
• Check Regulatory Eligibility: Confirm the registration status, approved indications, batch identification, expiration date and current prescribing information in the destination market. Korean approval does not establish authorization in another country.

Storage & Handling

HITOX must be stored under refrigeration at 2–8°C (36–46°F) in its original sealed container. Maintain the labeled storage conditions throughout warehousing and distribution.

The Korean regulatory records identify a shelf life of 24 months for HITOX 50U and 36 months for HITOX 100U and 200U. Verify the expiration date and current storage instructions on the original commercial packaging.

HITOX is supplied as a vacuum-dried powder, not a ready-to-use injectable liquid. Preparation, administration and handling after preparation must follow the product-specific prescribing information. Do not use expired products or vials with damaged or compromised packaging.

Botulinum toxin products carry important safety warnings, including the potential for toxin effects to spread beyond the injection site. Serious adverse reactions may include muscle weakness, difficulty swallowing, breathing difficulties and hypersensitivity reactions. Administration is restricted to appropriately qualified healthcare professionals.

Frequently Asked Questions